ABSTRACT
Based on serum pharmacochemistry and network pharmacology, the pharmacodynamic material basis and mechanism of Xiangju tablets (XJPs) in the treatment of rhinitis and sinusitis were discussed. UPLC‐QTOF‐MS/MS technology combined with Compound Discover 3.0 was used to analyze and identify the in vivo and in vitro components of XJP. The blood components of XJP were obtained. The protein interaction network was constructed by network pharmacology, combined with GO functional analysis and KEGG enrichment analysis to reveal the key active components and potential mechanism of XJP in the treatment of rhinitis and sinusitis. A total of 423 compounds were identified in XJP, of which 41 were blood components, including gallic acid, chlorogenic acid, caffeic acid, epicatechin, rutin, rosmarinic acid, and linarin. These active components may regulate PI3K‐Akt, MAPK, Ras, Rap1, and other signaling pathways through key targets such as GAPDH, MAPK3, SRC, AKT1, CASP3, and IL6. XJP exerts the effect of treating rhinitis and sinusitis through multicomponent–multitarget–multipathway. This study provides a reference for the study of the mechanism of XJP in the treatment of rhinitis and sinusitis and provides new ideas for the development of new dosage forms for targeted treatment of rhinitis and sinusitis.
Keywords: network pharmacology, rhinitis, sinusitis, UPLC‐QTOF‐MS/MS, Xiangju tablets
1. Introduction
Rhinitis and sinusitis are inflammatory disorders affecting the nasal cavity and paranasal sinus mucosa, respectively. These two conditions frequently coexist and together represent a highly prevalent disease spectrum in otolaryngology (Eifan and Durham 2016; Wilcox et al. 2025). The clinical manifestations of rhinitis include nasal congestion, rhinorrhea, nasal pruritus, sneezing, and hyposmia. Chronic rhinitis, defined as symptom duration exceeding 4 weeks, not only impairs quality of life but also constitutes a risk factor for asthma (Yang et al. 2025). Sinusitis is among the most common otorhinolaryngological diseases, with a global prevalence of 8%–12%, and imposes a substantial burden on patients' quality of life (Platt et al. 2025). According to current pathophysiological understanding, the core mechanism underlying sinusitis involves dysregulation of inflammatory signaling. Following stimulation of the sinonasal mucosa by pathogens and allergens, proinflammatory pathways are overactivated, leading to eosinophilic or neutrophilic infiltration, mucus hypersecretion, and disruption of the epithelial barrier (Dorismond et al. 2025). Currently, the mainstay of clinical treatment for rhinitis and sinusitis includes intranasal glucocorticoids, antihistamines, and leukotriene receptor antagonists (Cobanoğlu et al. 2013). Although these agents provide rapid symptomatic relief, their clinical use is associated with certain limitations (Ai et al. 2023). These shortcomings underscore the urgent need for safe, effective, and multitarget therapeutic alternatives.
Xiangju tablets (XJPs) represent a compound‐formulated traditional Chinese medicine developed from a folk prescription. Its key medicinal component originates from characteristic herbal resources of the Qinba Mountain area, and XJP was selected as a high‐priority variety of “Qinyao” (Shaanxi‐origin medicinal herbs) in Shaanxi Province in 2020. XJP is composed of Platycarya strobilacea , Prunella vulgaris , Chrysanthemum indicum , Astragalus membranaceus, Saposhnikoviae Radix, Magnoliae Flos, and other Chinese medicines. Clinical observations have demonstrated that this preparation exerts comprehensive therapeutic effects, including dispelling wind‐pathogens and clearing heat to unblock nasal orifices, whereby multiple symptoms such as nasal congestion, rhinorrhea, and headache can be alleviated. Improved therapeutic outcomes have been reported for combined therapy of XJP with N‐acetylcysteine nebulization in pediatric acute sinusitis. Compared with monotherapy, this combined regimen yields a higher overall clinical response rate, accelerates the resolution of core symptoms including nasal congestion and purulent rhinorrhea, and induces more favorable improvement in sinus mucosal inflammation and drainage with acceptable safety profiles (Zhang 2025). Therapeutic benefits of XJP have also been documented for pediatric chronic sinusitis, with effective relief of clinical manifestations such as nasal congestion, purulent rhinorrhea and headache, and amelioration of sinus mucosal congestion, oedema, and drainage dysfunction (Chen et al. 2022). Cumulative clinical evidence suggests promising efficacy of XJP for the management of allergic rhinitis and sinusitis (Liu 2018). Nevertheless, the pharmacodynamic material basis and precise action mechanisms underlying XJP remain poorly characterized.
Serum pharmacochemistry of traditional Chinese medicine (TCM) is based on the analysis of serum collected from experimental animals at a designated time following oral administration, after the removal of endogenous proteins and other interfering substances. The components present in the serum are analyzed using modern separation and identification techniques, such as liquid chromatography coupled with mass spectrometry, thereby enabling the prediction of bioactive components and their metabolic processes in vivo (Chen et al. 2023; Wang et al. 2023). Following oral administration of TCM, the components that enter the bloodstream are considered to be the direct effectors of pharmacological activity (Wang 2002). Owing to its efficient separation capability and sensitive detection, LC‐MS technology has substantially improved the efficiency of qualitative and quantitative analyses of chemical constituents in TCM and provides reliable technical support for investigating the pharmacologically active ingredients of TCM formulations (Maimaitiaili et al. 2026). Network pharmacology, which is characterized by a systematic and holistic approach, has been employed to elucidate the mechanisms of action of TCM from a multicomponent, multitarget, and multipathway perspective (Zhai et al. 2025).
In the present study, UPLC‐QTOF‐MS/MS was employed to identify the blood‐entering components of XJP. Combined with network pharmacology analysis, a component‐target‐pathway network was constructed to systematically explore the potential pharmacodynamic material basis and predictive action characteristics of XJP. This study provides a theoretical reference for further investigations on the effective material basis of XJP and offers novel insights for the research and development of targeted preparations for the clinical treatment of rhinitis and sinusitis.
2. Materials and Methods
2.1. Materials and Animals
Formic acid and acetonitrile are from LC‐MS grade, Merck Group, Germany; phosphoric acid (chromatographic grade) is from Tianjin Komio Chemical Reagent Co. Ltd.; water is Wahaha pure water. XJPs are from Shaanxi Xiangju Pharmaceutical Group Co. Ltd.
Eight male Sprague–Dawley (SD) rats (body weight 200 ± 20 g) were purchased from Chengdu Dashuo Experimental Animal Co. Ltd. (License No. SCXK [Sichuan] 20190003). The animal experimental procedures of this study were approved by the Experimental Animal Welfare and Ethics Committee of Shaanxi University of Traditional Chinese Medicine (Approval Number SUCMDL20230327003).
2.2. Animal Experiment
2.2.1. Animal Grouping and Administration
XJPs were decoated and ground into a fine powder. The resulting powder was accurately weighed and dissolved in distilled water to obtain a gastric juice simulant with a mass concentration of 0.04 g/mL. The intragastric administration dose for rats was set at 0.4 g/(kg·day), which was equivalent to 10 mL/kg per rat, based on the clinical dose conversion. After 1 week of adaptive feeding, the rats were randomly divided into a blank control group and an administration group based on body weight, with four rats in each group. The administration group received XJPs at a dose of 0.4 g/kg by intragastric gavage, whereas the blank control group received an equivalent volume of distilled water once daily for three consecutive days. Following the final administration, all rats were fasted for 12 h with free access to water. Blood samples were collected 1.5 h after intragastric administration on the third day.
2.2.2. Preparation of Plasma Samples
Rats were anesthetized via intraperitoneal injection of pentobarbital sodium (30 mg/kg). Blood samples were harvested from the abdominal aorta and centrifuged at 3500 r/min for 15 min at 4°C using an H2‐16KR desktop refrigerated high‐speed centrifuge (Hunan Kecheng Instrument and Equipment Co. Ltd.). The resulting serum supernatant was transferred into 5‐mL centrifuge tubes. An aliquot (100 μL) of serum was mixed with three volumes of methanol in a 1.5‐mL centrifuge tube, vortex‐mixed for 3 min, and centrifuged at 12,000 r/min for 15 min. The supernatant was transferred to a 0.5‐mL tube and vacuum‐dried using a Bionoon Concentrator plus vacuum centrifugal concentrator (Shanghai Banuo Biotechnology Co. Ltd.) operated at 2000 r/min and 21.2°C. The dried residue was reconstituted with methanol, and the final supernatant was collected for subsequent UPLC‐QTOF‐MS/MS analysis.
2.3. UPLC‐QTOF‐MS/MS–Based Analysis of the Characteristic Components in the Blood of XJP
2.3.1. Chromatographic and Mass Spectrometric Conditions
An UHPLC‐MS/MS system consisting of a Vanquish UHPLC instrument and a Q‐Exactive Orbitrap mass spectrometer (Semmerfeld Technologies Inc., United States) was used. Separation was performed on a BEH C18 column (2.1 mm × 100 mm, 1.7 μm) at 35°C, with a mobile phase of 0.1% formic acid in water (A) and acetonitrile (B). The gradient program (0–1.5 min, 5% B; 1.5–14 min, 50% B; 14–20 min, 95% B; 20–26 min, 95% B; 26–26.1 min, 5% B; 26.1–30 min, 5% B) was run at 0.3 mL/min, and the injection volume was 5 μL.
Mass spectrometric detection was performed using an electrospray ionization (ESI) source operating in both positive and negative ion modes, with a mass resolution of 70,000. The sheath gas flow rate was set at 45 L/min and the auxiliary gas flow rate at 10 mL/min. The spray voltage was maintained at 3.5 kV, the ion transfer tube temperature at 275°C, and the auxiliary gas temperature at 450°C. Mass spectra were acquired over the mass range of m/z 100–1200. Data were collected from XJP samples, blank serum, and drug‐containing serum. Raw data files were processed using CD3.0 software for feature extraction. Compound identification was performed by matching the characteristic peaks against the mzCloud, mzVault, and OTCML databases simultaneously, with a screening threshold of a matching score > 80. The MS and MS/MS spectral information of the annotated compounds was further compared with reference standards and relevant literature data for final confirmation.
2.3.2. Preparation of Sample Solution and Standard Solution
The coating of XJP pills was removed before fine grinding. A weighed portion of the powder was put into a 1‐g stoppered conical flask. Add exactly 25 mL of methanol and record the total weight. Ultrasonic extraction lasted 45 min (power: 250 W, frequency: 40 kHz). After the liquid had cooled to room temperature, methanol was added to restore its original weight, and the solution was thoroughly mixed. The solution was filtered through a 0.22‐μm organic needle filter to obtain an XJP sample solution with a concentration of 0.04 g/mL.
2.4. Network Pharmacology Study on the Entrance Components of XJP
2.4.1. Target Prediction Analysis of Blood Components of Xiangju Tablets
Compound structures were retrieved from the PubChem database (https://pubchem.ncbi.nlm.nih.gov/) and downloaded as SDF (*.sdf) files, which were then converted to canonical SMILES format. The resulting SMILES strings were submitted to the SwissTargetPrediction platform (http://www.swisstargetprediction.ch/) for target prediction, with the species limited to Homo sapiens and a probability threshold of > 0. All predicted targets were collected, and duplicate entries were removed to generate a nonredundant target list for further analysis.
2.4.2. Prediction Analysis of Disease‐Related Targets
The disease‐related protein genes were predicted and analyzed by GeneCards (http://www.genecards.org/), OMIM (https://omim.org/), PharmGKB (https://www.pharmgkb.org/), TTD (https://db.idrblab.net/ttd/), and DrugBank (https://www.drugbank.com/) five disease target databases. Given that XJP is clinically indicated for the management of acute and chronic sinusitis and rhinitis, search terms “acute sinusitis,” “chronic sinusitis,” “acute rhinitis,” and “chronic rhinitis” were employed to extract relevant disease targets from the five aforementioned databases. Retrieved target genes were merged, and duplicate entries were eliminated to yield the final list of disease‐associated targets.
2.4.3. Construction of “Blood Components–Disease–Target” Network of XJP
The intersection targets between the blood‐absorbed components of XJPs and the diseases were obtained using the Venny 2.1 online analysis tool. These overlapping targets were considered as the potential therapeutic targets of XJPs in the treatment of acute and chronic sinusitis and rhinitis. The “blood component–target–disease” interaction network was constructed and visualized using Cytoscape 3.8.2 software.
2.4.4. PPI Network Construction
The overlapping targets were uploaded to the STRING database (https://cn.string‐db.org/) to construct a protein–protein interaction (PPI) network model, with the species restricted to H. sapiens and the confidence threshold set at > 0.9. The PPI network file was downloaded and imported into Cytoscape 3.9.1 software for visualization and topological analysis. Nodes with closeness, betweenness, and degree centrality values greater than their respective means were selected as hub targets, which were considered to be the key therapeutic targets of XJPs in the treatment of acute and chronic sinusitis and rhinitis.
2.4.5. GO and KEGG Functional Enrichment Analysis
For Gene Ontology (GO) and KEGG pathway enrichment analyses, the hub targets were uploaded to the Metascape database (https://metascape.org/gp/) with a significance threshold of p < 0.01. The enrichment results, including biological process (BP), molecular function (MF), cellular component (CC), and KEGG pathways, were obtained and systematically analyzed. The data were then visualized for further interpretation. Subsequently, Cytoscape software was employed to construct the “blood component–hub target–pathway” network diagram.
3. Results
3.1. Analysis of Chemical Constituents of XJP
Total ion current (TIC) chromatograms were acquired in both positive and negative ion modes, as shown in Figure 1. Based on literature data, comparison with reference standards, and database matching, a total of 423 compounds were identified from XJPs. These included flavonoids, terpenoids, organic acids, coumarins, phenols, sugars, and their derivatives.
FIGURE 1.

The TIC diagram of positive ion mode (A) and negative ion mode (B). (a: XJP; b: blank serum; and c: medicated serum).
Through comparative analysis between blank serum and drug‐containing serum samples, 41 components of rat blood were analyzed and identified. Further comparison between XJP sample solution and rat serum samples enabled the identification of 41 prototype components in serum (Table S1). Based on CD3.0 auxiliary analysis and comparative database and literature research, these components were identified as coumarins (2), lignans (3), flavonoids (17), triterpenes (4), alkaloids (1), organic acids (7), cycloastragenol saponins (1), phthalides (1), volatile oils (1), anthraquinones (1), and others (3). The specific results are shown in Table S1 (by retention time). Figure 2 is the molecular structure of 41 components. Figure 3 presents the MS/MS spectra of four representative blood‐entering components, namely linarin, magnoflorine, cimifugin, and magnolin.
FIGURE 2.

Molecular structure diagram of blood components of Xiangju tablets.
FIGURE 3.

Secondary mass spectrometry of some blood components. (A) Linarin, (B) magnoflorine, (C) cimifugin, and (D) magnoli.
3.1.1. Identification of Flavonoids
The majority of flavonoids are found as glycosides, and glycosidic linkages are frequently disrupted. They will become aglycones after losing the glycosyl group, shedding more neutral pieces like CO and CH3, and their C ring is vulnerable to reverse Diels‐Alder (RDA) breakage (Zhang, Li, et al. 2025). Compound 28 (tR = 9.255 min) displayed a quasimolecular ion at m/z 593.1854 [M + H]+, corresponding to the molecular formula C28H32O14, as deduced from its elemental composition. The molecular ion lost one molecule of rhamnose to form the fragment ion m/z 447.1282 [M + H‐C6H10O4]+, which then lost the ‐C6H10O5 group to become the ion fragment m/z 285.0754 [M + H‐C12H20O9]+. After comparison, it was found that the retention time, molecular ion, and secondary fragment information of the compound were consistent with the buddleoside reference substance and literature reports (Zhang, Chen, et al. 2025). The possible cleavage pathway is shown in Figure 4A. Compound 12 (tR = 7.405 min) showed a quasimolecular ion peak at m/z 307.1170 [M + H]+ in positive ion mode. High‐resolution mass spectrometry (HRMS) analysis indicated its elemental composition to be C16H18O6. Major fragment ions included m/z 289.1065 [M + H − H2O]+ (dehydration product) and further successive loss of two methyl groups (‐CH3) yielding m/z 259.0599 [M + H − H2O − 2CH3]+. The furan ring of [M + H]+ at m/z 307.1170 was cleaved to produce [M + H‐C4H8O]+ at m/z 235.0598, and this fragment continued to lose CH2 to form [M + H‐C4H8O‐CH2]+ fragment ions at m/z 221.0441. According to the relevant literature, it is speculated that compound 12 is cimifugin (Huang et al. 2025), and its possible cleavage pathway is shown in Figure 4B.
FIGURE 4.

Possible cleavage pathways of linarin (A) and cimifugin (B).
3.1.2. Identification of Alkaloids Compounds
In the positive ion mode, the quasimolecular ion peak of Compound 6 (tR = 6.083) is m/z 342.1695 [M]+, and its molecular formula is speculated to be C20H24NO4. After the parent ion was broken, the dimethylamino side chain was removed to form an ion fragment m/z 297.1119 [M‐NH (CH3)2]+. A molecule of CH3 continues to be lost, generating the characteristic ion fragment m/z 282.0884 [M‐NH (CH3)2‐CH3]+. Subsequently, the hydroxyl group was further lost, forming an ion fragment m/z 265.0858 [M‐NH (CH3)2‐CH3‐OH]+. The intermediate product can be further cleaved by structural rearrangement, losing carbonyl and methyl successively, and finally producing ion fragments of m/z 237.0908 [M‐NH (CH3)2‐CH3‐OH‐CO]+ and m/z 222.0675 [M‐NH (CH3)2‐CH3‐OH‐COCH3]+, respectively. Compound 6 was identified as magnoflorine by reference substance comparison and reference to relevant literature (Wang et al. 2025), and its possible cleavage pathway is shown in Figure 5.
FIGURE 5.

The possible cleavage pathway of magnolinine.
3.1.3. Identification of Lignans Compounds
The quasimolecular ion peak of Compound 32 (tR = 12.665) is m/z 417.1897 [M + H]+. According to the elemental composition, the chemical formula is speculated to be C23H28O7. The fragment ion m/z 399 is produced by the excimer ion losing one H2O molecule. Continue to lose one H2O molecule to obtain a fragment ion of m/z 381. By comparing the cleavage pathway with the literature (Wu et al. 2026), it is preliminarily speculated that compound 32 is magnolin, and its possible cleavage pathway is shown in Figure 6.
FIGURE 6.

The possible cleavage pathway of magnolin.
3.2. Network Pharmacological Analysis of Blood Components
3.2.1. Analysis of Blood Component Targets and Disease‐Related Targets of XJP
A database search identified 35 blood components with known targets (Table 1). In total, 560 targets were collected for these compounds, and 4204 disease‐related targets were retrieved from the databases. The overlap between the two sets was analyzed using Venny 2.1, which yielded 305 common targets (Figure 7A).
TABLE 1.
Information on 35 targeted blood components.
| No. | Compound | Molecular formula |
|---|---|---|
| R1 | Gallic acid | C7H6O5 |
| R2 | Chlorogenic acid | C16H18O9 |
| R3 | Caffeic Acid | C9H8O4 |
| R4 | (+)‐Magnoflorine | C20H23NO4 |
| R5 | Apigenin 7‐glucuronide | C21H18O11 |
| R6 | Isovitexin | C21H20O10 |
| R7 | Isoliquiritigenin | C15H12O4 |
| R8 | Cynaroside | C21H20O11 |
| R9 | Kaempferol‐3‐Glucuronide | C21H18O12 |
| R10 | Cimifugin | C16H18O6 |
| R11 | Trifolin | C21H20O11 |
| R12 | Apigenin‐7‐O‐β‐D‐glucoside | C21H20O10 |
| R13 | Naringenin‐7‐glucoside | C21H22O10 |
| R14 | Naringenin | C15H12O5 |
| R15 | Rutin | C27H30O16 |
| R16 | Epicatechin | C15H14O6 |
| R17 | 7,3′,4′‐Trihydroxyflavanone | C15H12O5 |
| R18 | Diosmetin‐7‐O‐β‐D‐glucopyranoside | C22H23O11 |
| R19 | Rosmarinic acid | C18H16O8 |
| R20 | Ononin | C22H22O9 |
| R21 | Daidzein | C15H10O4 |
| R22 | Linarin | C28H32O14 |
| R23 | Astragaloside IV | C41H68O14 |
| R24 | (+)‐Eudesmin | C22H26O6 |
| R25 | 1,6‐Dimethoxynaphthalene | C12H12O2 |
| R26 | Magnolin | C23H28O7 |
| R27 | Epimagnolin B | C23H28O7 |
| R28 | Fargesin | C21H22O6 |
| R29 | Archin | C15H10O5 |
| R30 | Enoxolone | C30H46O4 |
| R31 | 12‐methoxycarnosic acid | C21H30O4 |
| R32 | Glabrolide | C30H44O4 |
| R33 | Oleanonic acid | C30H46O3 |
| R34 | Ursolic acid | C30H48O3 |
| R35 | Monoammonium Glycyrrhizinate | C42H65NO16 |
FIGURE 7.

Network pharmacology analysis of Xiangju tablets in the treatment of acute and chronic rhinitis and acute and chronic sinusitis. (A) Blood components‐disease target Venn diagram. (B) Xiangju tablet–blood components–target map. (C) PPI network diagram. (D) GO analysis. (E) KEGG analysis. (F) Blood components‐key targets‐pathway network diagram.
3.2.2. Construction of XJP‐Blood Component‐Target Network
Cytoscape 3.9.1 was used to construct a compound‐target network of XJP based on its blood‐entering components and corresponding targets. A total of 341 nodes and 1012 interaction pairs were included in this network. In the network graph, triangles stand for XJP, circles represent blood‐entering components, and squares represent intersecting disease targets. Node size corresponds to the degree value, and larger nodes indicate greater topological importance. The top 10 components with the highest degree values were screened as the core active components of XJP (Table 2). These results suggest that XJP may exert therapeutic effects on rhinitis and sinusitis through a multicomponent and multitarget regulatory mechanism.
TABLE 2.
Core component information.
| No. | Compounds | Degree |
|---|---|---|
| R1 | Gallic acid | 63 |
| R2 | Chlorogenic acid | 58 |
| R3 | Caffeic Acid | 58 |
| R15 | Rutin | 55 |
| R16 | Epicatechin | 52 |
| R19 | Rosmarinic acid | 51 |
| R22 | Buddleoside | 47 |
| R35 | Monoammonium glycyrrhizinate (ammonium glycyrrhizinate) | 46 |
| R25 | 1,6‐Dimethoxynaphthalene | 43 |
| R10 | Cimifugin | 39 |
3.2.3. Construction of PPI Interaction Network
The intersection targets were imported into the STRING database, saved in TSV format, and then loaded into Cytoscape 3.9.1 to construct a PPI network, as illustrated in Figure 7B. Based on the degree of connectivity, the top 10 targets were identified as core targets, with the screening process detailed in Figure 7C. These core targets include GAPDH, MAPK3, SRC, AKT1, CASP3, IL6, EGFR, VEGFA, HSP90AA1, and JUN, suggesting they serve as the central nodes linking the chemical constituents of XJP to disease‐related gene networks. Among these, IL‐6 and JUN are proinflammatory cytokines known to stimulate the synthesis of various inflammatory factors, thereby causing damage to the nasal mucosa (Lambertsen et al. 2012). MAPK3, a member of the MAPK family, activates inflammatory factor expression in IL‐13‐induced nasal epithelial cells and regulates T‐cell proliferation and differentiation (Wang et al. 2016). SRC, an intracellular nonreceptor tyrosine kinase, modulates IL‐4 and IL‐13‐induced inflammatory gene expression and effector functions, thereby influencing the development of allergic rhinitis (AR) (Shankar et al. 2022). Similarly, AKT1 plays a critical role in various biological processes, including cell survival, proliferation, and metabolism. Its signaling pathway is essential for maintaining the viability and physiological function of nasal mucosal epithelial cells and protecting the nasal mucosal barrier, both of which are closely linked to the onset and progression of AR (Wei et al. 2021).
3.2.4. GO and KEGG Enrichment Analysis
GO functional enrichment analysis of the core targets was conducted using the Metascape platform. Figure 7D displays the top 10 biological processes, cellular components, and molecular functions identified.
A total of 216 pathways were identified through KEGG enrichment analysis. The top 20 signaling pathways, focusing on those related to disease, were selected for the KEGG enrichment map (Figure 7E). As illustrated, these pathways are primarily associated with inflammation and disease. Inflammation‐related pathways include PI3K‐Akt, MAPK, Ras, and Rap1, whereas disease‐related pathways encompass cancer, proteoglycans in cancer, human cytomegalovirus infection, and Kaposi's sarcoma‐associated herpesvirus infection.
The PI3K‐AKT signaling pathway is essential for controlling cell proliferation, migration, and apoptosis. Chen et al. (2025) demonstrated that bavachinin mitigates LPS‐induced inflammation and barrier impairment in nasal epithelial cells by suppressing the PI3K/AKT/NF‐κB signaling pathway, while also inhibiting NLRP3 inflammasome activation and pyroptosis. The MAPK signaling pathway serves as a primary regulator in the pathogenesis of RS. Its subtypes, including p38 MAPK, c‐Jun N‐terminal kinase (JNK), and extracellular signal‐regulated kinase (ERK), drive RS progression by facilitating the release of proinflammatory cytokines, triggering apoptosis in nasal mucosal epithelial cells, and stimulating polyp development (Zhang, Wang, et al. 2025). The Ras and Rap1 signaling pathways are involved in cell growth, differentiation, proliferation, and metabolism and act synergistically to activate the ERK cascade via cyclic adenosine monophosphate (cAMP) signaling (Li et al. 2016).
3.2.5. Construction of Blood Components‐Key Targets‐Pathways Network
Cytoscape software was used to construct a network of blood components–key targets–pathways, as shown in Figure 7F. Higher connectivity of a component in the network indicates a higher probability that the component exerts therapeutic effects on the relevant disease via key targets. Among them, the degree values of eight components related to the efficacy were greater than the average degree values, which were gallic acid, chlorogenic acid, caffeic acid, epicatechin, rutin, rosmarinic acid, linarin, and ammonium glycyrrhetate. These components are potential important components for the clinical efficacy of XJP.
The oral bioavailability (OB) predicted by the TCMSP database was further used as an auxiliary index to prioritize the above eight blood‐entry components. With OB > 30% as the condition, four components were screened out: gallic acid (31.69%), caffeic acid (54.97%), epicatechin (48.96%), and linarin (39.84%).
Previous studies have reported that gallic acid exerts antiallergic activity, partly by modulating the levels of several key immunoglobulins (IgE, IgG1, and IgG2a) (Shen et al. 2022). These antibodies are related to the cytokine‐controlled B‐cell immune response of helper T cells. Caffeic acid, epicatechin, and ammonium glycyrrhizinate are rich in traditional Chinese medicine and have good anti‐inflammatory effects (Yu et al. 2020; Wu et al. 2020; Maione et al. 2019). Chlorogenic acid and rosmarinic acid have a regulatory effect on allergic rhinitis (Xu et al. 2025; Zhou et al. 2021). Previous studies have demonstrated that rutin exhibits anti‐inflammatory and antibacterial properties and can produce immunomodulatory effects in mice (Wang et al. 2022). Linarin has anti‐inflammatory and antibacterial effects and exists in a variety of rhinitis preparations as a characteristic component of quality control (Zhang et al. 2013; Lin and Mao 2018).
4. Discussion
In this study, blood samples collected at a single time point were utilized for network pharmacology‐based prediction of the characteristic components of XJPs and their potential functions. However, it should be acknowledged that qualitative serum pharmacochemical analysis based on single time‐point sampling cannot fully capture the dynamic processes of absorption, exposure, and elimination of the related components in vivo. Consequently, the prototype components detected in the 41 serum samples merely represent those that were measurable under the specific administration and sampling conditions employed. Components with earlier or later peak times, lower blood concentrations, or rapid elimination kinetics may have escaped detection. Furthermore, no quantitative pharmacokinetic analysis was performed in the present study. As a result, the actual in vivo exposure levels of individual components and their relative contributions to the therapeutic efficacy could not be evaluated based on the current data. Therefore, the network pharmacology analysis conducted herein, which was grounded on the identified blood‐borne components, serves primarily as a screening tool for candidate pharmacodynamically relevant compounds, potential targets, and associated signaling pathways. The results should be interpreted as mechanistic predictions rather than conclusive validations. In future investigations, integration of multitime‐point blood sampling, targeted quantitative analysis, and systematic pharmacokinetic studies will be necessary to further elucidate the in vivo exposure characteristics of the prioritized candidate components and to establish their correlation with pharmacodynamic outcomes.
5. Conclusions
In this study, UPLC‐QTOF‐MS/MS technology was integrated with network pharmacology to analyze the blood‐absorbed components of XJPs and to predict their mechanisms of action. Gallic acid, chlorogenic acid, caffeic acid, epicatechin, rutin, rosmarinic acid, buddleoside, and ammonium glycyrrhetate were identified as potential effective components for the treatment of acute and chronic rhinitis and sinusitis. These components were predicted to exert anti‐inflammatory effects through targeting key proteins including MAPK3, SRC, AKT1, CASP3, and IL6 and by modulating multiple signaling pathways, such as PI3K‐Akt, MAPK, Ras, and Rap1. This study provides a useful reference for further investigation into the pharmacodynamic material basis of XJPs.
Author Contributions
Xuan Wei: formal analysis; investigation; writing. Qiong Qu: visualization. Yingying Tang: assisted with the experiment. Xuan Lei: assisted with the experiment. Xi Duan: conceptualization. Xiao Song: project administration; funding acquisition.
Funding
This work was supported by the Xianyang Municipal Bureau of Science and Technology (L2024‐QCY‐ZYYJJQ‐X50) and the Shaanxi Provincial Department of Science and Technology (S2026‐YF‐YBSF‐1480).
Conflicts of Interest
The authors declare no conflicts of interest.
Supporting information
Table S1: The blood components of Xiangju Tablets.
Acknowledgements
This work is supported by the project of Xianyang Science and Technology Bureau (L2024‐QCY‐ZYYJJQ‐X50) and the Shaanxi Provincial Department of Science and Technology (S2026‐YF‐YBSF‐1480).
Contributor Information
Xi Duan, Email: 465038301@qq.com.
Xiao Song, Email: song-xiaoyao@163.com.
Data Availability Statement
The data that support the findings of this study are available in the Supporting Information.
References
- Ai, C. , Zou Y., Liu H., Yang Z., and Xi J.. 2023. “Traditional Chinese Herbal Medicine for Allergic Diseases: A Review.” American Journal of Chinese Medicine 51, no. 4: 779–806. 10.1142/S0192415X23500374. [DOI] [PubMed] [Google Scholar]
- Chen, J. , Han Z., Mu K., and Zhang G.. 2022. “Efficacy of Fragrant Chrysanthemum Tablets in the Treatment of Chronic Sinusitis in Children [in Chinese].” Chinese Medical Digest (Otorhinolaryngology) 37, no. 02: 23–25+29. [Google Scholar]
- Chen, T. , Dong L., Wu Y., et al. 2025. “Bavachinin Alleviates Allergic Rhinitis by Modulating Gut Microbiota and Inhibiting NLRP3‐Mediated Epithelial Pyroptosis Through PI3K/AKT/NF‐κB Signaling Pathway.” Cellular Signalling 135: 112026. 10.1016/j.cellsig.2025.112026. [DOI] [PubMed] [Google Scholar]
- Chen, W. , Jie X., Chen T., Zhang Y., and Hao X.. 2023. “Status Quo of Research on the Serum Pharmaceutical Chemistry of Chinese Materia Medica [in Chinese].” China Medicine and Pharmacy 13, no. 04: 26–29+86. 10.3969/j.issn.2095-0616.2023.04.008. [DOI] [Google Scholar]
- Cobanoğlu, B. , Toskala E., Ural A., and Cingi C.. 2013. “Role of Leukotriene Antagonists and Antihistamines in the Treatment of Allergic Rhinitis.” Current Allergy and Asthma Reports 13, no. 2: 203–208. 10.1007/s11882-013-0341-4. [DOI] [PubMed] [Google Scholar]
- Dorismond, C. , Trivedi Y., Krysinski M. R., et al. 2025. “Effects of Inflammatory Endotypes on Disease Trajectory in Chronic Rhinosinusitis With Nasal Polyps.” Journal of Allergy and Clinical Immunology 156, no. 1: 139–149.e4. 10.1016/j.jaci.2025.03.029. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Eifan, A. O. , and Durham S. R.. 2016. “Pathogenesis of Rhinitis.” Clinical & Experimental Allergy 46, no. 9: 1139–1151. 10.1111/cea.12780. [DOI] [PubMed] [Google Scholar]
- Huang, F. , Song Y., Zuo T., et al. 2025. “Identification of the Components of Yu‐Ping‐Feng‐San Absorbed Into Plasma Based on UPLC‐Q‐TOF‐MS [in Chinese].” Journal of Nanjing University of Traditional Chinese Medicin 41, no. 5: 637–651. 10.14148/j.issn.1672-0482.2025.0637. [DOI] [Google Scholar]
- Lambertsen, K. L. , Biber K., and Finsen B.. 2012. “Inflammatory Cytokines in Experimental and Human Stroke.” Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism 32, no. 9: 1677–1698. 10.1038/jcbfm.2012.88. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Li, Y. , Dillon T. J., Takahashi M., Earley K. T., and Stork P. J.. 2016. “Protein Kinase A‐Independent Ras Protein Activation Cooperates With Rap1 Protein to Mediate Activation of the Extracellular Signal‐Regulated Kinases (ERK) by cAMP.” Journal of Biological Chemistry 291, no. 41: 21584–21595. 10.1074/jbc.M116.730978. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lin, C. , and Mao J.. 2018. “Simultaneous Determination of Chlorogenic Acid, Ferulic Acid and Buddleoside in Biyanyu Mixture by HPLC [in Chinese].” Frontiers in Pharmaceutical Sciences 21, no. 08: 1488–1490. 10.3969/j.issn.1008-049X.2018.08.047. [DOI] [Google Scholar]
- Liu, J. 2018. “Effect of Montelukast Sodium Combined With Xiangju Tablets in the Treatment of Allergic Rhinitis [in Chinese].” Clinical Research and Practice 3, no. 35: 132–133. 10.19347/j.cnki.2096-1413.201835061. [DOI] [Google Scholar]
- Maimaitiaili, T. , Wu M., Liu L., Chen F., and Abudurexiti A.. 2026. “Application of LC‐MS Technology in the Analysis of Chinese Herbal Medicine [in Chinese].” Central South Pharmacy 24, no. 02: 171–180. [Google Scholar]
- Maione, F. , Minosi P., di Giannuario A., et al. 2019. “Long‐Lasting Anti‐Inflammatory and Antinociceptive Effects of Acute Ammonium Glycyrrhizinate Administration: Pharmacological, Biochemical, and Docking Studies.” Molecules (Basel, Switzerland) 24, no. 13: 2453. 10.3390/molecules24132453. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Platt, M. P. , Gray S. T., and Peters A. T.. 2025. “Phenotype to Endotype—The Future of Chronic Rhinosinusitis.” JAMA 334, no. 11: 955–957. 10.1001/jama.2025.10887. [DOI] [PubMed] [Google Scholar]
- Shankar, A. , McAlees J. W., and Lewkowich I. P.. 2022. “Modulation of IL‐4/IL‐13 Cytokine Signaling in the Context of Allergic Disease.” Journal of Allergy and Clinical Immunology 150, no. 2: 266–276. 10.1016/j.jaci.2022.06.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Shen, N. , Luo S., Qiao X., and Zhang J.. 2022. “Study on the Anti‐Allergic Effect of Gallic Acid in Mice With Allergic Rhinitis [in Chinese].” Chinese Journal of Clinical Pharmacology 38, no. 05: 409–412. [Google Scholar]
- Wang, B. , Gao Y., Zheng G., et al. 2016. “Platycodin D Inhibits Interleukin‐13‐Induced the Expression of Inflammatory Cytokines and Mucus in Nasal Epithelial Cells.” Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie 84: 1108–1112. 10.1016/j.biopha.2016.10.052. [DOI] [PubMed] [Google Scholar]
- Wang, H. , Wang L., Guo S., et al. 2022. “Rutin‐Loaded Stimuli‐Responsive Hydrogel for Anti‐Inflammation.” ACS Applied Materials & Interfaces 14, no. 23: 26327–26337. 10.1021/acsami.2c02295. [DOI] [PubMed] [Google Scholar]
- Wang, W. , Feng J., Yang K., et al. 2025. “Pharmacodynamic Substances and Mechanism of Action of Huanglian Jiedu Decoction in the Treatment of Gouty Arthritis: A Study Based on UPLC‐Q‐TOF/MS, Network Pharmacology, and Molecular Docking Simulation [in Chinese].” Journal of Chongqing Medical University 50, no. 7: 860–869. 10.13406/j.cnki.cyxb.003855. [DOI] [Google Scholar]
- Wang, X. 2002. “Study on Serum Pharmacochemistry of Traditional Chinese Medicine and Traditional Chinese Medicine Compound [in Chinese].” Modernization of Traditional Chinese Medicine and Materia Medica‐World Science and Technology 02: 1–4+78. 10.3969/j.issn.1674-3849.2002.02.001. [DOI] [Google Scholar]
- Wang, Y. , Wang P., Wang W., Qin X., and Gao X.. 2023. “Integrative Dynamic PK‐PD Correlation Analysis and Its Application in Discovery of Pharmacodynamic Material Basis of Traditional Chinese Medicine [in Chinese].” Drug Evaluation Research 46, no. 06: 1157–1167. [Google Scholar]
- Wei, X. , Zhang B., Liang X., et al. 2021. “Higenamine Alleviates Allergic Rhinitis by Activating AKT1 and Suppressing the EGFR/JAK2/c‐JUN Signaling.” Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 86: 153565. 10.1016/j.phymed.2021.153565. [DOI] [PubMed] [Google Scholar]
- Wilcox, J. , Lobo D., and Anderson S.. 2025. “Sinusitis.” Primary Care; Clinics in Office Practice 52, no. 1: 87–97. 10.1016/j.pop.2024.09.010. [DOI] [PubMed] [Google Scholar]
- Wu, H. , Xie Y., Xu Y., et al. 2020. “Protective Effect of Epicatechin on APAP‐Induced Acute Liver Injury of Mice Through Anti‐Inflammation and Apoptosis Inhibition.” Natural Product Research 34, no. 6: 855–858. 10.1080/14786419.2018.1503261. [DOI] [PubMed] [Google Scholar]
- Wu, Y. , He K., Luo P., et al. 2026. “Multifaceted Mechanistic Exploration of Geranium wilfordii Maxim. in Asthma Treatment: Integrating Network Pharmacology, Machine Learning, Mendelian Randomization and Experimental Validation.” Frontiers in Cell and Developmental Biology 14: 1761424. 10.3389/fcell.2026.1761424. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Xu, X. , Wang L., Wu G., and Li X.. 2025. “Therapeutic Effects of Chlorogenic Acid on Allergic Rhinitis Through TLR4/MAPK/NF‐κB Pathway Modulation.” Biomolecules & Biomedicine 25, no. 7: 1571–1580. 10.17305/bb.2024.11582. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Yang, X. , Eremeeva K., Svistushkin V., Lisenkova D., Smolyarchuk E., and Nedorubov A.. 2025. “Variants of Rhinitis Medicamentosa Treatment: A Systematic Review.” European Archives of Oto‐Rhino‐Laryngology 282, no. 9: 4407–4416. 10.1007/s00405-025-09344-6. [DOI] [PubMed] [Google Scholar]
- Yu, L. , Qiu Q., Zhen D., Zhen H., Lu X., and Guo Y.. 2020. “Simultaneous Determination of Protocatechuic Acid and Caffeic Acid in Anti‐Inflammatory Active Parts of Sauropus spatulifolius by HPLC [in Chinese].” West China Journal of Pharmaceutical Sciences 35, no. 06: 640–643. [Google Scholar]
- Zhai, Y. , Liu L., Zhang F., et al. 2025. “Network Pharmacology: A Crucial Approach in Traditional Chinese Medicine Research.” Chinese Medicine 20, no. 1: 8. 10.1186/s13020-024-01056-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zhang, B. , Li Y., Jiang L., et al. 2025. “Identification of Chemical Constituents in Equisetum hyemale L. Based on UPLC‐Q‐Exactive‐Plus‐Orbitrap‐MS [in Chinese].” Chemical Reagents 47, no. 4: 94–104. [Google Scholar]
- Zhang, F. , Wang Y., Lin Y., Xing X., and Mao D.. 2025. “Research Progress on the Mechanism of Traditional Chinese Medicine Regulating MAPK Signaling Pathway in the Treatment of Sinusitis [in Chinese].” Journal of Sichuan of Traditional Chinese Medicine 43, no. 11: 210–216. [Google Scholar]
- Zhang, N. , Chen J., Zhou C., et al. 2025. “Analysis on Material Basis of Chaihu Qinggan Decoction and Its Tissue Distribution Characteristics in Mice by UHPLC‐Q‐Orbitrap‐HRMS [in Chinese].” Chinese Traditional and Herbal Drugs 56, no. 14: 4947–4965. 10.7501/j.issn.0253-2670.2025.14.003. [DOI] [Google Scholar]
- Zhang, W. , Wu M., and Xia L.. 2013. “Simultaneous Determination of Paeoniflorin and Linarin in Fangzhi Biyan Tablets by RRLC [in Chinese].” Journal of Chinese Medicinal Materials 36, no. 08: 1353–1355. [Google Scholar]
- Zhang, Z. 2025. “Efficacy and Safety Analysis of Xiangju Tablets Combined With n‐Acetylcysteine Aerosol Inhalation in the Treatment of Acute Sinusitis in Children [in Chinese].” Contemporary Medical Symposium 23, no. 27: 130–132. [Google Scholar]
- Zhou, L. , Han Z., Zhang R., et al. 2021. “Protective Effect of Rosmarinic Acid on Oxidative Stress Reaction of Allergic Rhinitis Induced by PM2.5 [in Chinese].” Chinese Journal of Ophthalmology and Otorhinolaryngology 21, no. 04: 276–281. [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Table S1: The blood components of Xiangju Tablets.
Data Availability Statement
The data that support the findings of this study are available in the Supporting Information.
